Clinical challenges with CDK46 inhibitors

Published Alicia Mew on Fri, 12/15/2023 - 10:25

VCCC Alliance Breast Cancer Grand Round with Prof Adam Brufsky

Clinical challenges with CDK46 inhibitors

15 November 2023

Since their approval in 2015, CDK46 inhibitors have revolutionised the therapy of hormone receptor-positive metastatic breast cancer. Despite this success, several challenges remain.

International speaker Prof Adam Brufsky will discuss these challenges and provide possibilities for our next steps forward.

Aim: To provide possibilities for the next steps forward with CDK46 inhibitors

Learning Objective: In this session, you will gain insights into:

  • the clinical challenges with CDK46 inhibitors

  • the most appropriate CDK46 inhibitor to give, and in what clinical situation. 

  • the clinical and molecular nature of CDK46 inhibitor resistance

  • therapies that are appropriate at progression after CDK46 inhibition

The VCCC Alliance Breast Cancer Grand Rounds is targeted at a clinical audience and features open discussion about real cases and patients. While these cases are de-identified, the imagery, content and discussion can be graphic. It is not appropriate for consumer participants.


Dr Belinda Yeo
Medical Oncologist, Austin Health and Clinician Scientist, Olivia Newton-John Cancer Research Institute, La Trobe University; Breast Cancer Research & Education Lead, VCCC Alliance

Dr Belinda Yeo is jointly appointed to Austin Health as a Medical Oncologist and to the Olivia Newton-John Cancer Research Institute (ONJCRI) as a Clinician Scientist with a specific interest in breast cancer. She trained in Sydney before joining the Breast Unit at The Royal Marsden Hospital, London as a Clinical and Research Fellow. She completed a Master’s degree at the University of London and the Institute of Cancer Research in novel genomic and non-molecular breast cancer risk assays in hormone receptor positive breast cancer.

She continues her translational research at the ONJCRI investigating improving personalisation and minimising toxicities for patients with breast cancer. Through the Translational Breast Cancer Program at ONJCRI, she has established a Breast Cancer Biobank focusing on the collection of real-time primary and metastatic tumour specimens for translational analysis. Dr Yeo is the principal investigator on multiple breast cancer clinical trials, including an investigator-initiated pilot study to evaluate the decision impact for a non-molecular marker for hormone receptor positive breast cancer to improve clinical and patient decision-making.


Prof Adam Brufsky
Professor of Medicine, Co-Director, Comprehensive Breast Cancer Program UPMC Hillman Breast Cancer Center, University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania

Prof Brufsky is board-certified in internal medicine and medical oncology by the American Board of Internal Medicine and an active member of the American Society of Clinical Oncology and the American Association for Cancer Research. He has published numerous abstracts and research articles in leading journals, including the Journal of Clinical Investigation, Journal of Clinical Oncology and Lancet. Prof Brufsky is principal investigator on a number of research grants funded by the National Institutes of Health, the Susan G. Komen Foundation and the U.S. Army Breast Cancer Research Program.

He is currently the principal investigator of the Pittsburgh Breast Cancer Consortium, a US Department of Defense-funded program to increase community access to innovative clinical trials for the treatment of metastatic breast cancer, as well as a number of other breast cancer studies.

Course Details

Microscope lens
Course type
60 mins
Curriculum Area
Clinical Care
Research (incl. Clinical Trials)
Clinical trials
Clinical trials

This course is brought to you by